Navigation Links
Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
Date:8/16/2011

st and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143 (formerly NV-143). The second is a mitochondrial inhibitor program that includes lead candidate ME-344 (formerly NV-344). The Company expects to initiate a Phase I clinical trial of intravenous ME-143 by September 2011 and submit an Investigational New Drug application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
2. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
3. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
4. Marshall Edwards Announces Private Placement
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Receives Positive Response From NASDAQ
7. Marshall Edwards to Host Annual Meeting of Stockholders
8. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
9. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
10. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 /PRNewswire/ ... that it will release its second quarter 2014 financial ... 31, 2014. In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the Wedbush Life Sciences Conference in New York on ... Interested parties may access a live audio webcast of the ... www.BMRN.com .  A replay of the call will be ...
... Merck,s Schering-Plough unit current and former pharmaceutical representatives ... opinion issued by a Federal Court in Connecticut. ... The law firms of Joseph, Herzfeld, Hester ... represent the plaintiffs in a Nationwide Collective Law Suit. ...
Cached Medicine Technology:BioMarin to Present at the Wedbush Life Sciences Conference 2UPDATE: Total Victory for Schering-Plough (Now Merck) Pharmaceutical Reps in National Suit for Overtime Pay 2
(Date:7/24/2014)... July 25, 2014 Voted one of ... the global clients, BellasDress focuses on providing its new ... fashion information. Recently, the company has announced its new ... the new range is created according to the latest ... discounts, up to 68% off. , As a matter ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... Just as fitness and health professionals ... own financial and marketing strength to be important as ... the next level by using the most powerful communication ... Broadcast, Call Tracking and SMS texting solutions . ... messages are quickly become integral in marketing and communication ...
(Date:7/24/2014)... its 2014 Power of A Award winners, including two ... , The ASA Global Humanitarian Outreach (GHO) program ... the top honors from ASAE. GHO was honored for ... on the global anesthesia crisis and supporting low income ... honored with a Power of A Silver Award for ...
(Date:7/24/2014)... appears to increase the risk for head and neck cancer ... with DM, but the risk of HNC in patients with ... cancer is the sixth most common type of cancer. It ... an estimated 650,000 new cancer cases and 350,000 cancer deaths ... Insurance Research Database to examine the risk of HNC in ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3
... sites nationwide, - Triples network bandwidth to more than 1 Gbps at ... ... solution, ROCHESTER, N.Y., March 18 Time Warner Telecom,Inc. (Nasdaq: ... businesses, today announced a multi-year, contract,to deploy an eight-site IP VPN solution ...
... PartsSource, the nation,s,leading supplier of replacement medical repair ... Team NEO award. Team NEO recognizes,the exceptional companies ... as the engines fueling the Cleveland area economy., ... what,s right about Northern Ohio,business," said President & ...
... Using data from the SCIAMACHY instrument aboard ESA,s Envisat ... regionally elevated atmospheric carbon dioxide the most important ... from manmade emissions. , More than 30 billion tonnes ... into the atmosphere annually by human activities, mainly through ...
... New U of T research holds promise for ... serve as a model for future therapies against the ... Stagljar, University of Toronto scientists have identified several compounds ... ExoS). One of these compounds, exosin, significantly inhibited infections ...
... March 18 On The Go,Healthcare, Inc. (OTC ... computer hardware, software and systems integrator,announced today that ... the Company has sold its Value Added Reseller ... (OTC Bulletin Board: FLIP). The,terms of the sale, ...
... or not relatives talk about the familys history of ... and testing for those at moderate risk of developing ... today at the American Society for Preventive Oncology meeting ... African Americans participate less often in genetic counseling and ...
Cached Medicine News:Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 2Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 3Health News:Envisat makes first ever observation of regionally elevated CO2 from manmade emissions 2Health News:Envisat makes first ever observation of regionally elevated CO2 from manmade emissions 3Health News:Research promising for cystic fibrosis 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Family communication impacts attitude about genetic counseling/testing for breast cancer 2
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures....
... Webster is the source for a complete ... catheters for left-sided mapping - all with ... come to expect from the leader in ... sinus diagnostic catheters are specifically designed and ...
... Inquiry 5FR Soft HIS diagnostic ... a uniquely designed curve that ... in the HIS bundle. In ... designed to reduce the risk ...
Standard Deflectable Catheters...
Medicine Products: